Owens & Minor Inc. (NYSE:OMI) shares traded -2.18% lower at $19.30 on Wall Street last session.
In accordance with the data, 7 analysts cover Owens & Minor Inc. (NYSE:OMI). The consensus rating among analysts is ‘Hold’. As we calculate the median target price by taking the range between a high of $23.00 and a low of $17.00, we find $21.00. Given the previous closing price of $19.73, this indicates a potential upside of 6.44 percent. OMI stock price is now 0.79% away from the 50-day moving average and -35.76% away from the 200-day moving average. The market capitalization of the company currently stands at $1.46B.
It has been rated a hold by 4 analysts and a buy by 1. Brokers who have rated the stock have averaged $20.67 as their price target over the next twelve months.
With the price target reduced from $52 to $18, Citigroup Downgraded its rating from Buy to Neutral for Owens & Minor Inc. (NYSE: OMI). On October 12, 2022, Robert W. Baird Downgraded its previous ‘Outperform’ rating to ‘Neutral’ on the stock reducing its target price from $62 to quote $22, while ‘BofA Securities’ rates the stock as ‘Underperform’.
In other news, Henkel Robert J, Director bought 1,000 shares of the company’s stock on Oct 17. The stock was bought for $15,680 at an average price of $15.68. Upon completion of the transaction, the Director now directly owns 28,000 shares in the company, valued at $0.54 million. An SEC document containing details of the transaction can be found on the SEC’s website. On Jul 15, Director Henkel Robert J bought 1,000 shares of the business’s stock. A total of $31,760 was incurred on buying the stock at an average price of $31.76. This leaves the insider owning 27,000 shares of the company worth $0.52 million. Insiders disposed of 971,529 shares of company stock worth roughly $18.75 million over the past 1 year. A total of 2.70% of the company’s stock is owned by insiders.
There have been several recent changes in the stakes of large investors in OMI stock. A new stake in Owens & Minor Inc. shares was purchased by BOSTON PARTNERS during the first quarter worth $11,689,000. MARSHALL WACE, LLP invested $2,772,000 in shares of OMI during the first quarter. In the first quarter, ENDURANT CAPITAL MANAGEMENT LP acquired a new stake in Owens & Minor Inc. valued at approximately $1,079,000. GRAHAM CAPITAL MANAGEMENT, L.P. acquired a new stake in OMI for approximately $897,000. PARALLAX VOLATILITY ADVISERS, L.P. purchased a new stake in OMI valued at around $851,000 in the second quarter.
Owens & Minor Inc. (NYSE: OMI) opened at $19.87 on Wednesday. During the past 12 months, Owens & Minor Inc. has had a low of $14.10 and a high of $49.11. As of last week, the company has a debt-to-equity ratio of 2.64, a current ratio of 1.50, and a quick ratio of 0.60. The fifty day moving average price for OMI is $19.15 and a two-hundred day moving average price translates $30.04 for the stock.
The latest earnings results from Owens & Minor Inc. (NYSE: OMI) was released for Jun, 2022. According to the Medical Distribution Company, earnings per share came in at $0.76, inline with analysts’ expectations of $0.76. This compares to $0.58 EPS in the same period last year. The net profit margin was 1.20% and return on equity was 12.80% for OMI. The company reported revenue of $2.5 billion for the quarter, compared to $2.5 billion a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue fell -0.19 percent. For the current quarter, analysts expect OMI to generate $2.4B in revenue.
Moreover, the firm recently paid out its quarterly dividend on 12/31/2021. Investors who held shares on 12/15/2021 were paid a $0.0025 dividend. On an annualized basis, this represents a $0.01 dividend and a 0.05% percent yield. There was an ex-dividend date of 12/14/2021 for this dividend. In terms of dividend payout ratio, OMI is presently at 0.20%.
Owens & Minor Inc.(OMI) Company Profile
Owens & Minor, Inc., together with its subsidiaries, operates as a healthcare solutions company in the United States and internationally. It operates through two segments, Global Solutions and Global Products. The Global Solutions segment offers a portfolio of products and services to healthcare providers and manufacturers. Its portfolio of medical and surgical supplies includes branded products and its proprietary products. This segment also offers services to healthcare providers, which include supplier management, analytics, inventory management, and clinical supply management; and various programs to provide logistics and marketing solutions to its suppliers. The Global Products segment manufactures and sources medical surgical products for the prevention of healthcare-associated infections across the acute and alternate site channels. This segments products portfolio includes sterilization wraps, surgical drapes and gowns, facial protection products, protective apparel, medical exam gloves, custom and minor procedure kits, and other medical products. It provides its products and services to multi-facility networks of healthcare providers, independent hospitals, surgery centers, physicians’ practices, and networks of hospitals directly, as well as indirectly through third-party distributors. The company was founded in 1882 and is headquartered in Richmond, Virginia.